Genentech

Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer

Retrieved on: 
Wednesday, January 4, 2023
Hoffmann-La Roche, IMS Health, Boehringer Ingelheim, Head, Genentech, University of London, Squamous cell carcinoma, RP1, RP2, Health, GSK, Skin, CSCC, RP3, University, Imperial College London, Center for Study of Science, Technology and Policy (CSTEP), Nursing, BCC, Marketing, Molecular biology, Management, Fine chemical, Sanofi, Biotechnology, Science, Medicine, Vismodegib, Biosimilar

“These leadership appointments provide broad strategic and operational commercial acumen as we ramp up our commercial planning ahead of the potential 2024 commercial launch of RP1,” said Philip Astley-Sparke, Chief Executive Officer of Replimune.

Key Points: 
  • “These leadership appointments provide broad strategic and operational commercial acumen as we ramp up our commercial planning ahead of the potential 2024 commercial launch of RP1,” said Philip Astley-Sparke, Chief Executive Officer of Replimune.
  • “Chris led the launch of Libtayo in cutaneous squamous cell carcinoma (CSCC) at Sanofi, and was also involved with the launch of Erivedge in basal cell carcinoma (BCC) when at Genentech.
  • Sush will partner with Chris on our go-to-market strategy in the U.S. with RP1 and also in defining our commercialization strategy for the rest of the world.
  • Chris began his career with GSK where he held several sales and marketing leadership roles of increasing responsibility.

Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors

Retrieved on: 
Wednesday, December 21, 2022
Cancer, Chemical engineering, Book, Biotechnology, Therapy, Drug development, Genentech, Patient, Gene expression, BIO, Degenerative disease, Safety, University, University of California, Davis, Bone marrow failure, RNA, Massachusetts Institute of Technology, Pharmaceutical industry

"We are pleased to welcome Dr. Cleland to our Board as we continue to design next-generation RNA therapeutics with our proprietary technologies.

Key Points: 
  • "We are pleased to welcome Dr. Cleland to our Board as we continue to design next-generation RNA therapeutics with our proprietary technologies.
  • His decades of expertise across the scientific and financial aspects of the industry will be invaluable to our clinical and business development strategies," said Akihiro Ko, chief executive officer of Elixirgen Therapeutics.
  • Dr. Cleland added, "I’m eager to join the Board as Elixirgen Therapeutics continues to demonstrate how their novel technology has the potential to be a key player in the rapidly-evolving RNA space.
  • I look forward to working with the Elixirgen Therapeutics team at this pivotal time in the Company’s growth."

Aerami Therapeutics Appoints Lisa Yañez as Chief Executive Officer

Retrieved on: 
Wednesday, December 21, 2022
City of London Finance Committee, Investigational New Drug, Biotechnology, Food, Pulmonary hypertension, Therapy, MD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Merck, United Therapeutics, GSK, Acceleron Pharma, University, FDA, American Board of Nuclear Medicine, Committee on Finance, Acceleron, PAH, Pharmaceutical industry, Genentech

DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Aerami Therapeutics Holdings, Inc (“Aerami”), a clinical-stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary and cardiometabolic conditions, today announced the appointment of Lisa Yañez as chief executive officer, effective January 1, 2023. As part of a planned leadership transition, Steve Thornton will retire as CEO at the end of the year but remain on the Board of Directors and assume the Chairmanship of the Finance Committee.

Key Points: 
  • DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Aerami Therapeutics Holdings, Inc (“Aerami”), a clinical-stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary and cardiometabolic conditions, today announced the appointment of Lisa Yañez as chief executive officer, effective January 1, 2023.
  • Ms. Yañez has more than 25 years of leadership experience at leading pharmaceutical and biotechnology companies, including Merck, Genentech, GSK, and most recently, United Therapeutics and Acceleron Pharma.
  • At United Therapeutics, Ms. Yañez led the multi-billion-dollar PAH franchise that includes five of the fifteen currently FDA-approved therapies for PAH.
  • “I look forward to continuing to work closely with her and her team at Aerami Therapeutics as they further develop AER-901 to address high unmet need for new therapeutic options.”

Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration

Retrieved on: 
Monday, December 19, 2022
BIIB, Hoffmann-La Roche, Economics, Food, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Genentech, Lymphatic system, Mantle cell lymphoma, CD3, Patient, Biogen, Antibody, Phase, CD20, EMA, Roche, Fine chemical, Vaccine, DLBCL

Under the terms of the agreement, Biogen will have no payment obligations and will receive tiered royalties on potential net sales of glofitamab within the United States as part of the companies long-standing collaboration on antibodies targeting CD20.

Key Points: 
  • Under the terms of the agreement, Biogen will have no payment obligations and will receive tiered royalties on potential net sales of glofitamab within the United States as part of the companies long-standing collaboration on antibodies targeting CD20.
  • Glofitamab is an investigational CD20xCD3 T-cell engaging bispecific antibody being developed by Roche for the treatment of B-cell non-Hodgkin’s lymphomas, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, and other blood cancers1.
  • If approved, glofitamab has the potential to be a first-in-class fixed-duration CD20xCD3 T-cell engaging bispecific antibody in DLBCL.
  • The companies have had a collaboration on antibodies targeting CD20 since 1995.

FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma

Retrieved on: 
Friday, January 6, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, The New England Journal of Medicine, Cancer, Hoffmann-La Roche, Priority review, Food, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Oxaliplatin, BLA, Lymphatic system, OR, Royal commission, Mantle cell lymphoma, DLBCL, NHL, HIV disease progression rates, Aggressive lymphoma, CAR, CRS, Patient, Cytokine release syndrome, ROG, RO, European Commission, FDA, Rituximab, Lymphoma, B-cell lymphoma, Phase, GemOx, Hematology, Incidence, Society, CR, Pharmaceutical industry, Genentech

The FDA is expected to make a decision on approval of this novel cancer immunotherapy by July 1, 2023.

Key Points: 
  • The FDA is expected to make a decision on approval of this novel cancer immunotherapy by July 1, 2023.
  • If approved, glofitamab would be the first fixed-duration, off-the-shelf CD20xCD3 T-cell engaging bispecific antibody available to treat people with an aggressive lymphoma who have previously received multiple courses of treatment.
  • The FDA will review the glofitamab BLA under the granted Fast Track Designation.
  • Glofitamab is part of Genentech’s industry-leading CD20xCD3 T-cell engaging bispecific antibody clinical program, which is the broadest and most advanced in lymphoma.

Nimble Therapeutics Announces Expansion of its Discovery and Development Partnership with Genentech

Retrieved on: 
Thursday, January 5, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Genentech, Hoffmann-La Roche, CSO, Partnership, RO, ROG, Roche, Therapy, Fine chemical, Nimble

“We are excited to significantly expand our partnership and strengthen our collaboration with Genentech,” said Jigar Patel, Founder & CEO of Nimble Therapeutics.

Key Points: 
  • “We are excited to significantly expand our partnership and strengthen our collaboration with Genentech,” said Jigar Patel, Founder & CEO of Nimble Therapeutics.
  • Nimble will apply its platform against multiple targets, and Genentech and Roche will be responsible for preclinical and clinical development, and commercialization of any resulting products.
  • “This expanded partnership with Genentech, and the multiple recently achieved milestones across all our partnered programs, demonstrates Nimble’s capability to deliver peptide therapeutic candidates,” said Pete Gough, CSO of Nimble Therapeutics.
  • Nimble is a biotechnology company dedicated to delivering on the promise of peptide therapeutics.

Wilson Electronics Acquires UK Based Zinwave; Now Delivers Globally the Most Comprehensive Fiber-based Wireless Coverage Solution

Retrieved on: 
Thursday, January 5, 2023
Mobile, Wireless, Technology, Telecommunications, DAS, Yale University, Distributed antenna system, Geography, Wilson, Electronics, Organization, Meta, Hardware, LTE, Acquisition, Hospital, Sky, OEM, University, CBRS, AstraZeneca, Mobile phone, Renewable energy, Genentech, Operation

With Zinwave’s custom-engineered, fully fiber-delivered Distributed Antenna Systems (DAS), Wilson will be able to serve all bands from 150 to 5,000 MHz simultaneously, without the need for additional Hardware.

Key Points: 
  • With Zinwave’s custom-engineered, fully fiber-delivered Distributed Antenna Systems (DAS), Wilson will be able to serve all bands from 150 to 5,000 MHz simultaneously, without the need for additional Hardware.
  • With this acquisition, Wilson Electronics’ fortifies their current offerings and solidifies their delivery of business continuity, employee and customer safety, great customer experiences, and mission-critical connectivity.
  • Not only is this a significant move from a technology standpoint, but it also strengthens and expands Wilson Electronics’ global presence.
  • Holding over 250 patents, Wilson Electronics leads the cellular signal amplification industry with their Distributed Antenna Systems (DAS).

Belharra Therapeutics Announces Broad Collaboration with Genentech to Discover and Develop Novel Medicines Across Multiple Therapeutic Areas

Retrieved on: 
Wednesday, January 4, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Hoffmann-La Roche, Therapy, MD, Sale, Disease, Patient, Proteome, Roche, Autoimmunity, Doctor of Philosophy, Neurodegeneration, Pharmaceutical industry, Fine chemical, Belharra, Genentech

Belharra Therapeutics, a privately held drug discovery company with a novel photoaffinity-based, non-covalent chemoproteomics platform, today announced a multi-year collaboration with Genentech, a member of the Roche Group.

Key Points: 
  • Belharra Therapeutics, a privately held drug discovery company with a novel photoaffinity-based, non-covalent chemoproteomics platform, today announced a multi-year collaboration with Genentech, a member of the Roche Group.
  • The companies will collaborate employing Belharra’s proprietary platform to discover and develop small molecule medicines in multiple therapeutic areas including oncology, immuno-oncology, autoimmune, and neurodegenerative diseases.
  • The company’s proprietary screening library enables Belharra scientists to identify any binding site, on any protein, in any conformational state, in any cell type.
  • “Partnering with early-stage companies like Belharra provides Genentech with yet another way to advance groundbreaking science to discover and develop medicines for patients with serious and life-threatening diseases.”

FoundationOne®Liquid CDx Receives FDA Approval as a Companion Diagnostic for Rozlytrek® (entrectinib)

Retrieved on: 
Wednesday, January 4, 2023
Research, FDA, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, Lung cancer, Cancer, Foundation Medicine, Hoffmann-La Roche, Liquid, Food, CGP, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Genentech, Breast, Patient, FDA, Entrectinib, Cholangiocarcinoma, ROS1, NSCLC, Sarcoma, Pharmaceutical industry, Medical device

FoundationOne Liquid CDx is the first and only blood-based companion diagnostic approved for Rozlytrek (entrectinib).

Key Points: 
  • FoundationOne Liquid CDx is the first and only blood-based companion diagnostic approved for Rozlytrek (entrectinib).
  • This decision from the FDA follows the approval of Foundation Medicine’s tissue-based comprehensive genomic profiling (CGP) test, FoundationOne®CDx, for the same therapy last year.
  • CGP has transformed the traditional ‘one-size fits-all’ approach to cancer and is an important tool for identifying rare and hard to find mutations, including ROS1 and NTRK.
  • Foundation Medicine’s two FDA-approved tests both meet rigorous analytical and clinical validation standards and demonstrate Foundation Medicine’s deep regulatory expertise – FoundationOne Liquid CDx has the broadest gene panel of any FDA-approved blood-based test, and the company’s tissue-based CGP test, FoundationOne CDx, was the first ever FDA-approved broad companion diagnostic test.

Spinal Muscular Atrophy Treatment Market Report 2022: Continued Product Approvals Bolsters 18.6% Annual Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 29, 2022
Health, Pharmaceutical, Clinical trial, Ageing, SMA, Gene therapy, EC, UNC Medical Center, Administration, Food, Therapy, Spinal muscular atrophy, Research, Genentech, Royal commission, USD, Disease, Growth, Patient, Novartis, MAP, Treatment, Route of administration, European Commission, Segmental analysis (biology), Food and Drug Administration, EMA, Diagnosis, PTC Therapeutics, Medical device, Pharmaceutical industry, Medical imaging, Coal, Nusinersen, Onasemnogene abeparvovec, Risdiplam

The global spinal muscular atrophy treatment market size is expected to reach USD 18.0 billion by 2030.

Key Points: 
  • The global spinal muscular atrophy treatment market size is expected to reach USD 18.0 billion by 2030.
  • In March 2021, PTC Therapeutics, Inc., received marketing approval for Evrysdi (risdiplam) from the EMA for the treatment of patient with type1, 2, and 3 spinal muscular atrophy.
  • Thus, increasing number of product approvals is expected to drive the spinal muscular atrophy treatment market.
  • For instance, in July 2021, F. Hoffmann-La Roche Ltd launched Evrysdi (risdiplam) for the treatment of patient with spinal muscular atrophy in India
    Chapter 4 Global Spinal Muscular Atrophy Treatment Market - Segment Analysis, By Type, 2018 - 2030 (USD Million)
    Chapter 5 Global Spinal Muscular Atrophy Treatment Market - Segment Analysis, by Treatment, 2018 - 2030 (USD Million)
    Chapter 6 Global Spinal Muscular Atrophy Treatment Market - Segment Analysis, By Drug, 2018 - 2030 (USD Million)
    Chapter 7 Global Spinal Muscular Atrophy Treatment Market - Segment Analysis, by Route of Administration, 2018 - 2030 (USD Million)
    Chapter 8 Spinal Muscular Atrophy Treatment Market: Segment Analysis, by Region, 2018 - 2030 (USD Million)
    Chapter 9 Global Spinal Muscular Atrophy Treatment Market: Competitive Analysis